Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2021 Jul 23;143(30):11751–11758. doi: 10.1021/jacs.1c05376

Fast Ion-Chelate Dissociation Rate for In Vivo MRI of Labile Zinc with Frequency-Specific Encodability

Nishanth D Tirukoti , Liat Avram , Talia Haris , Benjamin Lerner , Yael Diskin-Posner , Hyla Allouche-Arnon , Amnon Bar-Shir †,*
PMCID: PMC8397314  PMID: 34297566

Abstract

graphic file with name ja1c05376_0007.jpg

Fast ion-chelate dissociation rates and weak ion-chelate affinities are desired kinetic and thermodynamic features for imaging probes to allow reversible binding and to prevent deviation from basal ionic levels. Nevertheless, such properties often result in poor readouts upon ion binding, frequently result in low ion specificity, and do not allow the detection of a wide range of concentrations. Herein, we show the design, synthesis, characterization, and implementation of a Zn2+-probe developed for MRI that possesses reversible Zn2+-binding properties with a rapid dissociation rate (koff = 845 ± 35 s–1) for the detection of a wide range of biologically relevant concentrations. Benefiting from the implementation of chemical exchange saturation transfer (CEST), which is here applied in the 19F-MRI framework in an approach termed ion CEST (iCEST), we demonstrate the ability to map labile Zn2+ with spectrally resolved specificity and with no interference from competitive cations. Relying on fast koff rates for enhanced signal amplification, the use of iCEST allowed the designed fluorinated chelate to experience weak Zn2+-binding affinity (Kd at the mM range), but without compromising high cationic specificity, which is demonstrated here for mapping the distribution of labile Zn2+ in the hippocampal tissue of a live mouse. This strategy for accelerating ion-chelate koff rates for the enhancement of MRI signal amplifications without affecting ion specificity could open new avenues for the design of additional probes for other metal ions beyond zinc.

Introduction

Of the cations with a biological role, Zn2+ has garnered much interest due to (i) its involvement, as a tightly bound Zn2+, in the determination of the structure and activity of essential proteins1 and (ii) its role, as mobile Zn2+, in different secretion pathways of specific tissue.25 Labile Zn2+ was found in relatively large pools in the prostate’s epithelial cells,6 in the pancreatic β-cells,7 and in the hippocampal mossy fibers,8 and its distribution in these tissues was characterized using well-established Zn2+-specific fluorescent imaging probes.9,10 Extensively designed, these probes provide diverse affinity capabilities for Zn2+ to cover a wide range of cation concentrations, which varies between sub-nanomolar and millimolar in different tissues.1113 Such variability in Zn2+ affinities was obtained through either replacing the commonly used dipicolyl amine amine (DPA)14 binding motif with other binding moieties (e.g., thioether,15 pyrrole,16 thiophen,17 quinoline,18 or pyrazine19) or by reducing the rigidity of the Zn2+-sensors.20 However, although this has increased our knowledge of Zn2+ biology, the need for multiple fluorescent probes to map wide and diverse concentrations of the cation, and the reduced specificity, poor readouts of probes with very low Zn2+ affinity (with a Kd at the mM level), and the limited depth penetration of fluorescent light, even of probes based on a long wavelength,21 call for further developments.

The advances in the design and implementation of MRI-responsive sensors have led to the development of sensors for spatially mapping the distribution of metal ions noninvasively from the deep tissues of live subjects,2229 overcoming one of the major limitations of fluorescent-based probes. Specifically, for Zn2+, MRI-responsive agents have been in development for two decades using different strategies for MRI readout alternation,3040 resulting in a few that were demonstrated in vivo. In addition to cell-penetrable formulations designed to image regions of rich pools of labile zinc in the brain of live animals,22 other formulations were used to map cell-secreted Zn2+ from both pancreatic23 and prostate24 tissues upon glucose stimulation, which showed, in real time, longitudinal modulation in the labile Zn2+ pools in live intact subjects. These agents were based on a DPA binding motif, which tightly binds Zn2+ with a Kd at the nM range, and were further developed as probes with a lower affinity for Zn2+ (at the μM range)4143 to reduce background signals. Although this revolutionized the way secretory Zn2+ can be mapped upon external stimulation, further developments are still desired to grant MRI-responsive agents with much lower affinity capabilities, a wider range of Zn2+ concentration detectability, and spectrally resolved specificity.

A recent approach that combines 19F-MRI and chemical exchange saturation transfer (CEST)4447 was developed to map metal ions and was thus termed ion CEST (iCEST). This approach shows several benefits over other MRI strategies for which responsive contrast agents are being developed. Among these are (i) the ability to provide spectrally resolved specificity based on the chemical shift of the ion-bound ligand; (ii) the advantages of fast ion-ligand dissociation rates toward enhanced signal amplifications; (iii) the ability to “turn on” the MRI contrast at will; and (iv) the use of a fluorinated probe that does not interfere with the anatomical MRI observations. Nevertheless, the iCEST probes used thus far to map Zn2+ secretion in a prostate cancer model in vivo(48) experience very strong cation affinity (Kd in the nM range), which is far from ideal for the preservation of basal cationic levels. Moreover, and very importantly, their slow ion-chelate dissociation rates (koff = kex ≈ 20 s–1)45 result in a very low CEST signal enhancement, which further restricts, significantly, the dynamic range of concentrations of the ion that can be detected. Here, we show the design of a Zn2+-responsive MRI agent with improved readouts of low levels of the ion and NMR frequency-specificity compared to other competitive cations. Having rationalized a fluorinated chelate that weakly, but still with preserved high specificity, binds Zn2+, we were able to amplify signals from a wide range of biologically relevant concentrations of labile Zn2+ through reversible dynamic exchange, toward mapping pools of the cation in specific regions of the brain of a live animal, with no interference from competitive cations.

Results and Discussion

The chemical shift offset (Δω) between two exchanging pools of spins is at the core of any designed CEST agent49 and thus, for 19F-CEST-based studies.45,5054 This is mainly due to the fact that a larger Δω results in a reduced direct saturation effect, allowing the use of strong saturation powers for an enhanced CEST effect. Moreover, a larger Δω allows the use of CEST agents that are applicable under a faster exchange regime (fulfilling the condition Δω > kex)55 and, therefore, are detectable at much lower concentrations.56,57 Thus, as a first step in our design, three putative fluorinated derivatives of DPA were synthesized based on the common use of a DPA backbone in both fluorescent-7,8,14 and MRI-22,32responsive probes developed for imaging labile Zn2+ under physiological conditions. To this end, employing a reductive amination using ethanolamine and different fluoropicolinaldehydes (see Supporting Information), the fluorinated chelates 1, 2, and 3 were synthesized with a fluorine substitution at positions 6, 3, and 5 of their pyridine rings, respectively (Figure 1a). Then, their 19F-NMR spectra in the presence of Zn2+ were examined to determine the Δω between free and Zn2+-bound chelate (Figure 1b). For all three examined chelates, an additional 19F-NMR peak that represented a Zn2+-bound chelate was depicted, with a characteristic Δω (relative to that of a free chelate set at 0.0 ppm) of +1.3, −0.6, or +4.1 ppm in the presence of 1, 2, and 3, respectively.

Figure 1.

Figure 1

19F-NMR of fluorinated chelates designed for Zn2+ binding studies. (a) The chemical structure of the synthesized fluorinated chelates 1, 2, and 3 with the fluorine substituent at the 6, 3, and 5 positions of the pyridine ring, respectively. (b) Schematic illustration of the dynamic exchange process between the free and Zn2+-bound chelate and the obtained 19F-NMR spectrum of 1, 2, and 3 in the presence of Zn2+ at 25 °C (3 mM chelate and 0.6 mM ZnCl2 at 100 mM Hepes buffer, pH = 7.2, 9.4 T NMR). Shown are the chemical shift offsets (Δω) between the peak of the free chelate (set at 0.0 ppm) and the peak Zn2+-chelate complex.

Given that the largest Δω between free and Zn2+-bound chelate was identified for 3 (Δω = +4.1 ppm) with a fluorine substitution at position 5, we aimed to study the effect of the chelate structure on the obtained binding dynamic profile and the correspondent 19F-iCEST effect. To this end, another set of chelates was synthesized, namely, 4, 5, and 6 (Figure 2a and b), with the purpose of obtaining variable Zn2+-binding dynamics through the induction of a steric hindrance for Zn2+ binding (compare 3 to 4 and 5 to 6) or by elongating the distance between the two pyridine rings of the chelate (compare 3 to 5 and 4 to 6).20 The significant differences in the affinities of the four examined chelates to Zn2+ were manifested by the appearances of the 19F-NMR spectra of aqueous chelate:Zn2+ (3 mM:0.6 mM, which is a 5:1 ratio) solutions at 37 °C and a pH of 7.2 (Figure 2c).

Figure 2.

Figure 2

Zn2+-chelate exchange dynamics as a function of the chelate structure. (a) Synthetic route used for the synthesis of 3 and its methylated derivative 4. (b) Synthetic route used for the synthesis of 5 and its methylated derivative 6. (c) 19F-NMR spectra of 3 mM fluorinated chelates (36) in the presence of 0.6 mM Zn2+ at 37 °C and the obtained Δω between the peak of the free ligand (set at 0.0 ppm) and the Zn2+-bound ligand. (d) Representative 19F-iCEST spectra obtained for an aqueous solution of 3 mM of either of the chelates (from left to right: 3, 4, 5, or 6) in the presence of 30 μM Zn2+ at 37 °C. All NMR data were performed on aqueous solutions (100 mM Hepes buffer, pH = 7.2) at 37 °C with a 9.4 T NMR spectrometer. Reaction conditions: (i) 2-aminoethan-1-ol, NaBH(OAc)3; (ii) PPh3, CBr4; (iii) 2-aminoethan-1-ol, K2CO3.

While a narrow 19F-NMR peak was obtained for the 3:Zn2+ complex, evidence of a very slow exchange rate in the NMR time scale, a broader and lower peak was obtained for the 4:Zn2+ complex. The 19F-NMR peak of the 5:Zn2+ was significantly broader and lower compared to that obtained for 4:Zn2+ and 3:Zn2+ complexes, indicative of the fast dissociation rate (koff, also termed the exchange rate, kex, in CEST studies) between Zn2+-bound and free 5. The absence of the 19F-NMR peak for the 6:Zn2+ complex suggests that this system experiences very fast kex in the NMR time scale and, thus, is less likely to be considered as a 19F-iCEST sensor for Zn2+.

These differences in the 19F-NMR spectra of solutions of a Zn2+:chelate ratio of 1:5 were clearly reflected by the 19F-iCEST spectra obtained from solutions with reduced concentrations of the cation and a Zn2+:chelate ratio of 1:100 (Figure 2d). For example, in the presence 30 μM Zn2+ (3 mM chelate), only a 6% 19F-iCEST effect was obtained with probe 3, which had increased to 45% for probe 4. Such a dramatic signal amplification was enhanced even more when 5 was used as the putative probe. In the presence of 3 mM 5, a very large 19F-iCEST effect of 62% was obtained for 30 μM Zn2+, implying a relatively fast kex between Zn2+-bound and free 5. The absence of any 19F-iCEST effect for the solution of 6:Zn2+ reflects a very fast kex between Zn2+-bound and free 6 (or lack of binding), beyond that required to obtain a robust CEST effect (kex ≤ Δω).

Quantifying the kex values between Zn2+-bound and free chelate, for 35 (Figure 3a and Figure S1), further elaborated the relationship between the obtained 19F-iCEST effect, i.e., the signal amplification capabilities, and the kinetic properties of the complex. As qualitatively implied by the 1D-19F-NMR spectra (Figure 2c) and also reflected by the relatively low iCEST effect (Figure 2d), a very slow kex value (∼5 s–1) was obtained for 3, as expected for a chelate that strongly binds Zn2+. The dissociation rate of Zn2+ from its bound state to the steric-hindered 4 was indeed faster (kex = 55 ± 5 s–1) and resulted in a more pronounced iCEST effect. The fastest kex value, i.e., the dissociation rate (koff) of chelate-bound Zn2+, was found for 5 (845 ± 35 s–1), which explains the very weak and broad 19F-NMR peak of the Zn2+-5 complex (Figure 2c), which also translated to the largest 19F-iCEST effect (Figure 2d). These results show that, by introducing chemical modification to fluorinated chelates, we can modulate the ion-chelate binding kinetics characteristics (obtaining relatively fast koff) while preserving the spectral specificity of the bound cation (Δω of +3.2 ppm for the Zn2+-5 complex).

Figure 3.

Figure 3

Zn2+-chelate exchange dynamics as a function of the chelate structure. (a) Evaluated exchange rates kex (s–1) between Zn2+-bound and free chelate as determined for 3, 4, and 5. All NMR data were performed on aqueous solutions (100 mM Hepes buffer, pH = 7.2) at 37 °C with a 9.4 T NMR spectrometer. The X-ray crystal structures of the Zn2+-chelate complexes are shown for 3-Zn2+ (b), 4-Zn2+ (c), and 5-Zn2+ (d).

To further elaborate on the linkage between the structure of the obtained Zn2+ complex and its obtained kinetic properties, we aimed to crystallize the complexes of Zn-3, Zn-4, and Zn-5, which clearly reflected different chelating properties of the three fluorinated probes (Figure 3b–d and Supporting Information). In the obtained crystal of Zn-3, Zn2+ adopts an octahedral arrangement with coordination to three nitrogen atoms of the DPA motif, to the hydroxyl oxygen of the side arm, and to two water molecules (Figure 3b). The crystal structures of Zn-4 and Zn-5 revealed two different dimers of five-coordinate Zn2+ complexes. In both complexes, Zn2+ is coordinated to the three nitrogen atoms of the DPA motif and to the hydroxyl oxygen side arm. In the Zn-4 dimer both Zn2+ ions share coordination to the same water molecule (Figure 3c).

In the Zn-5 dimer both Zn2+ ions share a coordination to the hydroxyl side arm of itself and its adjacent neighbor (Figure 3d), which may further explain, in addition to the flexibility of the chelate achieved by its longer distance between the pyridine moieties, the loosened binding of Zn2+ to 5 and the obtained faster koff. The low binding affinity of 5 to Zn2+ (Kd = (5.5 ± 0.6) × 10–3 M, Table S1 and Figure S2), which is a result of chelating properties observed from the crystal structure of the Zn-5 complex (Figure 3d), is preferable to maintain the steady-state concentration of the cation in the studied region and to prevent its dissociation from proteins, where it plays a critical role in both structure and function.

Since 5 was identified as the fluorinated chelate with the preferred characteristics (Figures 2 and 3), it was used in a set of 19F-iCEST experiments with a range of Zn2+ concentrations (1–30 μM, Figure 4a). Indeed, as a result of its fast koff (kex = 845 ± 35 s–1), the use of 5 provided the ability to detect a relatively wide range of Zn2+ concentrations with a conventional 19F-MR setup based on the amplification principle of CEST, which depends, among other parameters, on kex.

Figure 4.

Figure 4

19F-iCEST Zn2+ sensitivity and selectivity using 5. (a) 19F-iCEST effect for 3 mM 5 as a function of Zn2+ concentration. (b) 19F-iCEST profile of 1 mM 5 and 500 nM Zn2+. (c) 19F-NMR spectra of 3 mM 5 in the presence of 0.6 mM Na+, K+, Mg2+, Ca2+, Mn2+, Fe2+, Co2+, Ni2+, Cu2+, and Zn2+ at 25 °C. (d) 19F-iCEST effect (Δω = 3.2 ppm) of 3 mM 5 and 30 μM (in 100 mM Hepes buffer, pH = 7.2) of s-block (Na+, K+, Mg2+, Ca2+) and d-block (Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Zn2+) metal ions obtained at 37 °C on a 9.4 T NMR spectrometer. (e) 19F-iCEST MRI: (i) schematic representation of the studied phantom composed of seven tubes containing 7 mM 5 and 100 μM cation, i.e., Ca2+ (#1), Cu2+ (#2), Mg2+ (#3), Na+ (#4), K+ (#5), and Zn2+ (#7). Tube #6 contained only 5; (ii) 1H-MRI; (iii) 19F-MRI obtained with a presaturation pulse applied at Δω = −3.2 ppm; (iv) 19F-MRI obtained with a presaturation pulse applied at Δω = +3.2 ppm; (v) 19F-iCEST map obtained by the subtraction of the image in (iv) from that in (iii) overlaid on 1H-MRI.

For example, a 5% 19F-iCEST effect was obtained for 1 μM Zn2+ in the presence of 3 mM 5 (3000:1 ratio of chelate:ion), which corresponds to a ×150 signal amplification. The fact that one can control the concentration of the 19F-iCEST probe in the solution allows detection of even lower concentrations of Zn2+. In this regard, by reducing the concentration of 5 to 1 mM, a 10% effect in the presence of 500 nM Zn2+ could be detected at the expected frequency (Figure 4b). This is one major advantage of iCEST over water proton-based CEST agents, in analogy to the hyperCEST-based approach,58,59 where the bulk pool of free imaging agent (the 19F-MR signal of 5 in this study) is controllable and very small in comparison to the bulk water signal in tissue. Thus, although the main limitation of iCEST is its sensitivity that is based on 19F-MR and therefore relies on the deliverable amount of 5 into the studied region, this approach allows the detection of very low concentrations of cations with no background signal from the surrounding tissue.

Given that 5 was identified as the preferable 19F-iCEST agent for labile Zn2+, its specificity to detect this cation was examined. To this end, the 19F-iCEST effect of 5 in the presence of competitive ions, either those that are abundant in biological systems (e.g., Na+, K+, Mg2+, or Ca2+) or those that might have shared similar affinities to a Zn2+ chelate (Fe2+, Mn2+, Cu2+), was studied. Importantly, even though 5 binds Zn2+ with reduced affinity, neither additional chelate-ion complex peaks in 19F-NMR studies (Figure 4c) nor a 19F-iCEST effect was obtained for this chelate in the presence of the other studied cations (Figure 4d and Figure S3). Such an ability to detect Zn2+ with ultimate specificity, which is manifested by a characteristic 19F-iCEST spectrum with a spectrally resolved 19F-CEST peak (at Δω = +3.2 ppm), is an advantage of the proposed platform over commonly used and very sensitive relaxation-based MRI agents that do not possess this unique feature. To further demonstrate this, a phantom composed of test tubes that contained different cations in the presence of 5 was prepared and studied using a 9.4 T MRI scanner (Figure 4e). As expected, the presence of 5 did not affect the overall 1H MRI contrast of the studied solution, implying on no effect on anatomical MR observation in in vivo studies. Similarly, when the saturation pulse was applied “off-resonance”, i.e., Δω = −3.2 ppm from the 19F-NMR frequency of 5, no difference could be detected when comparing the 19F-MRI signals of the examined tubes. Nevertheless, when the saturation pulse was applied at Δω = +3.2 ppm, the frequency offset of the 5-Zn2+ complex (Figure 2c and d and Figure S4), a clear reduction of the 19F-MRI signal of the tube containing the Zn2+ ion (center tube) could be depicted. This manifestation of frequency-specific detectability of the cation of interest is presented as a 19F-iCEST contrast map that could be further overlaid on 1H-MRI for the spatial display of Zn2+ in the examined tube.

Then, we examined the potential of 5 to be used for in vivo mapping of labile zinc pools. For that purpose, two different regions of the brain, which are known for their different endogenous labile Zn2+ levels, were targeted. The CA3 region of the hippocampus was chosen as a region-of-interest (ROI) that is rich with labile Zn2+ and the thalamus (TH) as an ROI with very low levels of labile Zn2+.60 After evaluating its biocompatibility, even at the high concentrations needed for 19F-MRI (Figure S5), and showing that the lipophilicity of 5 allows its intracellular delivery (Figure S6), it was delivered intracranially to either CA3 (Figure 5a) or TH (Figure 5b) through a continuous infusion in order to compensate for its fast washout from the brain (Figure S7). Ninety minutes from starting the infusion (0.25 μL/min), when the concentration of 5 was estimated to be 1.2 mM in the studied region (Figure S8), 19F-MRI data sets were acquired with a presaturation pulse applied at either “off-resonance” (Δω = −3.2 ppm) or “on-resonance” (Δω = +3.2 ppm). The 19F-iCEST maps were then derived by subtraction of the 19F-MRI obtained “on-resonance” from that obtained “off-resonance”. As expected from a labile-zinc-rich ROI (CA3, Figure 5a), a significant 19F-iCEST effect was obtained, which was represented as a Zn2+ map overlaid on a 1H-MRI anatomical view (Figure 5a, right). In contrast, when 5 was delivered to a region that was not expected to have high levels of labile Zn2+ (TH, Figure 5b), no pronounced difference between the two 19F-MRI data sets could be depicted and the obtained 19F-iCEST showed no signal (Figure 5b, right).

Figure 5.

Figure 5

In vivo19F-iCEST maps of labile Zn2+ pools in the mouse brain. Shown results for two regions of the brain: (a) CA3 in the hippocampus (zinc-rich ROI) or (b) the thalamus (TH, zinc-poor ROI). From left-to-right are the schematic illustration of the setup used to deliver 5 to either CA3 or TH, the1H-MRI, the19F-MRI S–Δω (presaturation pulse applied at Δω = −3.2 ppm, i.e., “off-resonance”), the 19F-MRI S+Δω (presaturation pulse applied at Δω = +3.2 ppm, i.e., “on-resonance”), and the 19F-iCEST contrast (Zn2+ map) obtained from subtracting 19F-MRI S+Δω from 19F-MRI S–Δω overlaid on the 1H-MRI. MRI scans were performed at 15.2 T. Infusion rate was set to 0.25 μL/min (of 10 mM 5 in PBS), and iCEST data acquisition started 90 min from the onset of the infusion of 5.

Quantifying the obtained results from a group of mice showed a significant difference between the 19F-iCEST effect for the two regions (Figure 6, CA3 vs TH, N = 7/group, p-value < 0.001), with an average 29 ± 5% signal change in the labile-Zn2+-rich ROI, CA3. Importantly, when the presaturation pulse was applied at Δω = ±18 ppm, no observable 19F-iCEST effect was depicted, even in CA3 (N = 7, Figure 6 and Figure S9), confirming that a significant effect is obtained only from a zinc-rich region (CA3) and only when the saturation pulse is applied at a specific frequency (Δω = +3.2 ppm).

Figure 6.

Figure 6

In vivo19F-iCEST quantification plot: The average percentile of 19F-iCEST contrast (SΔω+/SΔω–) as quantified in CA3 at Δω = 3.2 ppm (N = 7 mice) or Δω = 18 ppm (N = 7 mice), or in the TH (N = 7) at Δω = 3.2 ppm. Error bar denotes SEM, *p-value < 0.05, **p-value < 0.001, unpaired Student’s t test.

Conclusions

In conclusion, we showed here the design of a fluorinated chelate (5), which features a fast Zn2+-chelate dissociation rate and can be used for in vivo MRI mapping of labile Zn2+ with improved sensitivity and supreme specificity. Obtaining a fast kex of 845 ± 35 s–1, at which Zn2+-bound and unbound states of 5 exchanged, provided the capability to detect a wide range of the cation concentrations that can be mapped using a single molecular probe. This is in contrast to fluorescent probes, where multiple probes are needed to cover the expected concentrations, with high-affinity probes useful for mapping low pools of labile zinc, while low-affinity probes are a better fit for imaging high concentrations of the cation.20 Moreover, and in contrast to other imaging strategies where low binding affinities can compromise both the specificity over other competitive cations and the signal readout changes (i.e., contrast-to-noise ratio) upon ion-binding, we demonstrated that the weak binding of Zn2+ to 5 did not affect its Zn2+ specificity or detectability. Having demonstrated the ability to map labile Zn2+ pools in a deep tissue of live animals, the proposed 19F-iCEST approach should be further applied to study dynamic changes in the cation concentration as a result of external stimulation or as a result of pathological events.23,24,42,48 Although demonstrated here for Zn2+ imaging, the principles outlined in this work should be further extended to rationalize the design of new 19F-iCEST probes to detect other metal ions with biological relevance and significance,61 especially those that may be found either at very low concentrations or in a wide range of concentrations where multiple probes with different binding affinities are still needed.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/jacs.1c05376.

  • Chemical synthesis procedures, NMR and MRI studies, exchange rate (kex) evaluations, dissociation constant (Kd) measurements, crystallization protocol and crystal structure data, cell viability assay and in vivo experiments (PDF)

Accession Codes

CCDC 2084667–2084671 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

Author Contributions

The manuscript was written through contributions of all authors.

This work was supported by the Israel Science Foundation (ISF 1329/20).

The authors declare no competing financial interest.

Supplementary Material

ja1c05376_si_001.pdf (4.5MB, pdf)

References

  1. Alberts I. L.; Nadassy K.; Wodak S. J. Analysis of zinc binding sites in protein crystal structures. Protein Sci. 1998, 7 (8), 1700–16. 10.1002/pro.5560070805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cole T. B.; Wenzel H. J.; Kafer K. E.; Schwartzkroin P. A.; Palmiter R. D. Elimination of zinc from synaptic vesicles in the intact mouse brain by disruption of the ZnT3 gene. Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (4), 1716–21. 10.1073/pnas.96.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Costello L. C.; Franklin R. B. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998, 35 (4), 285–96. . [DOI] [PubMed] [Google Scholar]
  4. Chimienti F.; Devergnas S.; Favier A.; Seve M. Identification and cloning of a beta-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 2004, 53 (9), 2330–7. 10.2337/diabetes.53.9.2330. [DOI] [PubMed] [Google Scholar]
  5. Que E. L.; Bleher R.; Duncan F. E.; Kong B. Y.; Gleber S. C.; Vogt S.; Chen S.; Garwin S. A.; Bayer A. R.; Dravid V. P.; Woodruff T. K.; O’Halloran T. V. Quantitative mapping of zinc fluxes in the mammalian egg reveals the origin of fertilization-induced zinc sparks. Nat. Chem. 2015, 7 (2), 130–9. 10.1038/nchem.2133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ghosh S. K.; Kim P.; Zhang X. A.; Yun S. H.; Moore A.; Lippard S. J.; Medarova Z. A novel imaging approach for early detection of prostate cancer based on endogenous zinc sensing. Cancer Res. 2010, 70 (15), 6119–27. 10.1158/0008-5472.CAN-10-1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gee K. R.; Zhou Z. L.; Qian W. J.; Kennedy R. Detection and imaging of zinc secretion from pancreatic beta-cells using a new fluorescent zinc indicator. J. Am. Chem. Soc. 2002, 124 (5), 776–8. 10.1021/ja011774y. [DOI] [PubMed] [Google Scholar]
  8. Hirano T.; Kikuchi K.; Urano Y.; Nagano T. Improvement and biological applications of fluorescent probes for zinc, ZnAFs. J. Am. Chem. Soc. 2002, 124 (23), 6555–62. 10.1021/ja025567p. [DOI] [PubMed] [Google Scholar]
  9. Kikuchi K.; Komatsu K.; Nagano T. Zinc sensing for cellular application. Curr. Opin. Chem. Biol. 2004, 8 (2), 182–91. 10.1016/j.cbpa.2004.02.007. [DOI] [PubMed] [Google Scholar]
  10. Tomat E.; Lippard S. J. Imaging mobile zinc in biology. Curr. Opin. Chem. Biol. 2010, 14 (2), 225–30. 10.1016/j.cbpa.2009.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Nolan E. M.; Lippard S. J. Small-molecule fluorescent sensors for investigating zinc metalloneurochemistry. Acc. Chem. Res. 2009, 42 (1), 193–203. 10.1021/ar8001409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Carter K. P.; Young A. M.; Palmer A. E. Fluorescent sensors for measuring metal ions in living systems. Chem. Rev. 2014, 114 (8), 4564–601. 10.1021/cr400546e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Maret W. Analyzing free zinc(II) ion concentrations in cell biology with fluorescent chelating molecules. Metallomics 2015, 7 (2), 202–11. 10.1039/C4MT00230J. [DOI] [PubMed] [Google Scholar]
  14. Burdette S. C.; Walkup G. K.; Spingler B.; Tsien R. Y.; Lippard S. J. Fluorescent sensors for Zn(2+) based on a fluorescein platform: synthesis, properties and intracellular distribution. J. Am. Chem. Soc. 2001, 123 (32), 7831–41. 10.1021/ja010059l. [DOI] [PubMed] [Google Scholar]
  15. Nolan E. M.; Lippard S. J. The zinspy family of fluorescent zinc sensors: syntheses and spectroscopic investigations. Inorg. Chem. 2004, 43 (26), 8310–7. 10.1021/ic048778z. [DOI] [PubMed] [Google Scholar]
  16. Nolan E. M.; Jaworski J.; Racine M. E.; Sheng M.; Lippard S. J. Midrange affinity fluorescent Zn(II) sensors of the Zinpyr family: syntheses, characterization, and biological imaging applications. Inorg. Chem. 2006, 45 (24), 9748–57. 10.1021/ic061137e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nolan E. M.; Ryu J. W.; Jaworski J.; Feazell R. P.; Sheng M.; Lippard S. J. Zinspy sensors with enhanced dynamic range for imaging neuronal cell zinc uptake and mobilization. J. Am. Chem. Soc. 2006, 128 (48), 15517–28. 10.1021/ja065759a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nolan E. M.; Jaworski J.; Okamoto K.; Hayashi Y.; Sheng M.; Lippard S. J. QZ1 and QZ2: rapid, reversible quinoline-derivatized fluoresceins for sensing biological Zn(II). J. Am. Chem. Soc. 2005, 127 (48), 16812–23. 10.1021/ja052184t. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zhang X. A.; Hayes D.; Smith S. J.; Friedle S.; Lippard S. J. New strategy for quantifying biological zinc by a modified zinpyr fluorescence sensor. J. Am. Chem. Soc. 2008, 130 (47), 15788–9. 10.1021/ja807156b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Komatsu K.; Kikuchi K.; Kojima H.; Urano Y.; Nagano T. Selective zinc sensor molecules with various affinities for Zn2+, revealing dynamics and regional distribution of synaptically released Zn2+ in hippocampal slices. J. Am. Chem. Soc. 2005, 127 (29), 10197–204. 10.1021/ja050301e. [DOI] [PubMed] [Google Scholar]
  21. Zhang S.; Adhikari R.; Fang M.; Dorh N.; Li C.; Jaishi M.; Zhang J.; Tiwari A.; Pati R.; Luo F. T.; Liu H. Near-Infrared Fluorescent Probes with Large Stokes Shifts for Sensing Zn(II) Ions in Living Cells. ACS Sens 2016, 1 (12), 1408–1415. 10.1021/acssensors.6b00490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lee T.; Zhang X. A.; Dhar S.; Faas H.; Lippard S. J.; Jasanoff A. In vivo imaging with a cell-permeable porphyrin-based MRI contrast agent. Chem. Biol. 2010, 17 (6), 665–73. 10.1016/j.chembiol.2010.05.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Lubag A. J.; De Leon-Rodriguez L. M.; Burgess S. C.; Sherry A. D. Noninvasive MRI of beta-cell function using a Zn2+-responsive contrast agent. Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (45), 18400–5. 10.1073/pnas.1109649108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Clavijo Jordan M. V.; Lo S. T.; Chen S.; Preihs C.; Chirayil S.; Zhang S.; Kapur P.; Li W. H.; De Leon-Rodriguez L. M.; Lubag A. J.; Rofsky N. M.; Sherry A. D. Zinc-sensitive MRI contrast agent detects differential release of Zn(II) ions from the healthy vs. malignant mouse prostate. Proc. Natl. Acad. Sci. U. S. A. 2016, 113 (37), E5464–71. 10.1073/pnas.1609450113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Bar-Shir A.; Avram L.; Yariv-Shoushan S.; Anaby D.; Cohen S.; Segev-Amzaleg N.; Frenkel D.; Sadan O.; Offen D.; Cohen Y. Alginate-coated magnetic nanoparticles for noninvasive MRI of extracellular calcium. NMR Biomed. 2014, 27 (7), 774–83. 10.1002/nbm.3117. [DOI] [PubMed] [Google Scholar]
  26. Okada S.; Bartelle B. B.; Li N.; Breton-Provencher V.; Lee J. J.; Rodriguez E.; Melican J.; Sur M.; Jasanoff A. Calcium-dependent molecular fMRI using a magnetic nanosensor. Nat. Nanotechnol. 2018, 13 (6), 473–477. 10.1038/s41565-018-0092-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Barandov A.; Bartelle B. B.; Williamson C. G.; Loucks E. S.; Lippard S. J.; Jasanoff A. Sensing intracellular calcium ions using a manganese-based MRI contrast agent. Nat. Commun. 2019, 10 (1), 897. 10.1038/s41467-019-08558-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Savic T.; Gambino G.; Bokharaie V. S.; Noori H. R.; Logothetis N. K.; Angelovski G. Early detection and monitoring of cerebral ischemia using calcium-responsive MRI probes. Proc. Natl. Acad. Sci. U. S. A. 2019, 116 (41), 20666–20671. 10.1073/pnas.1908503116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Paranawithana N. N.; Martins A. F.; Clavijo Jordan V.; Zhao P.; Chirayil S.; Meloni G.; Sherry A. D. A Responsive Magnetic Resonance Imaging Contrast Agent for Detection of Excess Copper(II) in the Liver In Vivo. J. Am. Chem. Soc. 2019, 141 (28), 11009–11018. 10.1021/jacs.8b13493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Major J. L.; Parigi G.; Luchinat C.; Meade T. J. The synthesis and in vitro testing of a zinc-activated MRI contrast agent. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (35), 13881–6. 10.1073/pnas.0706247104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hanaoka K.; Kikuchi K.; Urano Y.; Narazaki M.; Yokawa T.; Sakamoto S.; Yamaguchi K.; Nagano T. Design and synthesis of a novel magnetic resonance imaging contrast agent for selective sensing of zinc ion. Chem. Biol. 2002, 9 (9), 1027–32. 10.1016/S1074-5521(02)00216-8. [DOI] [PubMed] [Google Scholar]
  32. Esqueda A. C.; Lopez J. A.; Andreu-de-Riquer G.; Alvarado-Monzon J. C.; Ratnakar J.; Lubag A. J.; Sherry A. D.; De Leon-Rodriguez L. M. A new gadolinium-based MRI zinc sensor. J. Am. Chem. Soc. 2009, 131 (32), 11387–91. 10.1021/ja901875v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Hanaoka K.; Kikuchi K.; Urano Y.; Nagano T. Selective sensing of zinc ions with a novel magnetic resonance imaging contrast agent. J. Chem. Soc, Perkin Transactions 2 2001, (9), 1840–1843. 10.1039/b100994j. [DOI] [Google Scholar]
  34. Mishra A.; Logothetis N. K.; Parker D. Critical in vitro evaluation of responsive MRI contrast agents for calcium and zinc. Chem. - Eur. J. 2011, 17 (5), 1529–37. 10.1002/chem.201001548. [DOI] [PubMed] [Google Scholar]
  35. Yu M.; Xie D.; Kadakia R. T.; Wang W.; Que E. L. Harnessing chemical exchange: (19)F magnetic resonance OFF/ON zinc sensing with a Tm(iii) complex. Chem. Commun. 2020, 56 (46), 6257–6260. 10.1039/D0CC01876G. [DOI] [PubMed] [Google Scholar]
  36. Wang G.; Angelovski G. Highly Potent MRI Contrast Agent Displaying Outstanding Sensitivity to Zinc Ions. Angew. Chem., Int. Ed. 2021, 60 (11), 5734–5738. 10.1002/anie.202014431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yu J.; Martins A. F.; Preihs C.; Clavijo Jordan V.; Chirayil S.; Zhao P.; Wu Y.; Nasr K.; Kiefer G. E.; Sherry A. D. Amplifying the sensitivity of zinc(II) responsive MRI contrast agents by altering water exchange rates. J. Am. Chem. Soc. 2015, 137 (44), 14173–9. 10.1021/jacs.5b09158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Bodenler M.; Malikidogo K. P.; Morfin J. F.; Aigner C. S.; Toth E.; Bonnet C. S.; Scharfetter H. High-Field Detection of Biomarkers with Fast Field-Cycling MRI: The Example of Zinc Sensing. Chem. - Eur. J. 2019, 25 (35), 8236–8239. 10.1002/chem.201901157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Srivastava K.; Ferrauto G.; Harris S. M.; Longo D. L.; Botta M.; Aime S.; Pierre V. C. Complete on/off responsive ParaCEST MRI contrast agents for copper and zinc. Dalton Trans 2018, 47 (33), 11346–11357. 10.1039/C8DT01172A. [DOI] [PubMed] [Google Scholar]
  40. Bonnet C. S.; Caille F.; Pallier A.; Morfin J. F.; Petoud S.; Suzenet F.; Toth E. Mechanistic studies of Gd3+-based MRI contrast agents for Zn2+ detection: towards rational design. Chem. - Eur. J. 2014, 20 (35), 10959–69. 10.1002/chem.201403043. [DOI] [PubMed] [Google Scholar]
  41. De Leon-Rodriguez L. M.; Lubag A. J.; Lopez J. A.; Andreu-de-Riquer G.; Alvarado-Monzon J. C.; Sherry A. D. A second generation MRI contrast agent for imaging zinc ions in vivo. MedChemComm 2012, 3 (4), 480–483. 10.1039/c2md00301e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Martins A. F.; Clavijo Jordan V.; Bochner F.; Chirayil S.; Paranawithana N.; Zhang S.; Lo S. T.; Wen X.; Zhao P.; Neeman M.; Sherry A. D. Imaging Insulin Secretion from Mouse Pancreas by MRI Is Improved by Use of a Zinc-Responsive MRI Sensor with Lower Affinity for Zn(2+) Ions. J. Am. Chem. Soc. 2018, 140 (50), 17456–17464. 10.1021/jacs.8b07607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Stasiuk G. J.; Minuzzi F.; Sae-Heng M.; Rivas C.; Juretschke H. P.; Piemonti L.; Allegrini P. R.; Laurent D.; Duckworth A. R.; Beeby A.; Rutter G. A.; Long N. J. Dual-modal magnetic resonance/fluorescent zinc probes for pancreatic beta-cell mass imaging. Chem. - Eur. J. 2015, 21 (13), 5023–33. 10.1002/chem.201406008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Bar-Shir A.; Gilad A. A.; Chan K. W.; Liu G.; van Zijl P. C.; Bulte J. W.; McMahon M. T. Metal ion sensing using ion chemical exchange saturation transfer 19F magnetic resonance imaging. J. Am. Chem. Soc. 2013, 135 (33), 12164–7. 10.1021/ja403542g. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Bar-Shir A.; Yadav N. N.; Gilad A. A.; van Zijl P. C.; McMahon M. T.; Bulte J. W. Single 19F probe for simultaneous detection of multiple metal ions using miCEST MRI. J. Am. Chem. Soc. 2015, 137 (1), 78–81. 10.1021/ja511313k. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Gilboa H.; Chapman B. E.; Kuchel P. W. 19F NMR magnetization transfer between 5-FBAPTA and its complexes. An alternative means for measuring free Ca2+ concentration, and detection of complexes with protein in erythrocytes. NMR Biomed. 1994, 7 (7), 330–8. 10.1002/nbm.1940070707. [DOI] [PubMed] [Google Scholar]
  47. Peng Q.; Yuan Y.; Zhang H.; Bo S.; Li Y.; Chen S.; Yang Z.; Zhou X.; Jiang Z. X. 19F CEST imaging probes for metal ion detection. Org. Biomol. Chem. 2017, 15 (30), 6441–6446. 10.1039/C7OB01068K. [DOI] [PubMed] [Google Scholar]
  48. Yuan Y.; Wei Z.; Chu C.; Zhang J.; Song X.; Walczak P.; Bulte J. W. M. Development of Zinc-Specific iCEST MRI as an Imaging Biomarker for Prostate Cancer. Angew. Chem., Int. Ed. 2019, 58 (43), 15512–15517. 10.1002/anie.201909429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Ward K. M.; Aletras A. H.; Balaban R. S. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J. Magn. Reson. 2000, 143 (1), 79–87. 10.1006/jmre.1999.1956. [DOI] [PubMed] [Google Scholar]
  50. Shusterman-Krush R.; Tirukoti N. D.; Bandela A. K.; Avram L.; Allouche-Arnon H.; Cai X.; Gibb B. C.; Bar-Shir A. Single Fluorinated Agent for Multiplexed 19F-MRI with Micromolar Detectability Based on Dynamic Exchange. Angew. Chem., Int. Ed. 2021, 60 (28), 15405–15411. 10.1002/anie.202100427. [DOI] [PubMed] [Google Scholar]
  51. Avram L.; Havel V.; Shusterman-Krush R.; Iron M. A.; Zaiss M.; Sindelar V.; Bar-Shir A. Dynamic Interactions in Synthetic Receptors: A Guest Exchange Saturation Transfer Study. Chem. - Eur. J. 2019, 25 (7), 1687–1690. 10.1002/chem.201806243. [DOI] [PubMed] [Google Scholar]
  52. Avram L.; Iron M. A.; Bar-Shir A. Amplifying undetectable NMR signals to study host-guest interactions and exchange. Chem. Sci. 2016, 7 (12), 6905–6909. 10.1039/C6SC04083G. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Shusterman-Krush R.; Grimm L.; Avram L.; Biedermann F.; Bar-Shir A. Elucidating dissociation activation energies in host-guest assemblies featuring fast exchange dynamics. Chem. Sci. 2021, 12 (3), 865–871. 10.1039/D0SC05666A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Goren E.; Avram L.; Bar-Shir A. Versatile non-luminescent color palette based on guest exchange dynamics in paramagnetic cavitands. Nat. Commun. 2021, 12 (1), 3072. 10.1038/s41467-021-23179-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Woods M.; Woessner D. E.; Sherry A. D. Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem. Soc. Rev. 2006, 35 (6), 500–11. 10.1039/b509907m. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Aime S.; Delli Castelli D.; Terreno E. Supramolecular adducts between poly-L-arginine and [TmIIIdotp]: a route to sensitivity-enhanced magnetic resonance imaging-chemical exchange saturation transfer agents. Angew. Chem., Int. Ed. 2003, 42 (37), 4527–9. 10.1002/anie.200352132. [DOI] [PubMed] [Google Scholar]
  57. Aime S.; Delli Castelli D.; Terreno E. Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. Angew. Chem., Int. Ed. 2005, 44 (34), 5513–5. 10.1002/anie.200501473. [DOI] [PubMed] [Google Scholar]
  58. Riggle B. A.; Wang Y.; Dmochowski I. J. A “Smart” 129Xe NMR Biosensor for pH-Dependent Cell Labeling. J. Am. Chem. Soc. 2015, 137 (16), 5542–8. 10.1021/jacs.5b01938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Schroder L.; Lowery T. J.; Hilty C.; Wemmer D. E.; Pines A. Molecular imaging using a targeted magnetic resonance hyperpolarized biosensor. Science 2006, 314 (5798), 446–9. 10.1126/science.1131847. [DOI] [PubMed] [Google Scholar]
  60. Frederickson C. J.; Koh J. Y.; Bush A. I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci. 2005, 6 (6), 449–62. 10.1038/nrn1671. [DOI] [PubMed] [Google Scholar]
  61. Domaille D. W.; Que E. L.; Chang C. J. Synthetic fluorescent sensors for studying the cell biology of metals. Nat. Chem. Biol. 2008, 4 (3), 168–75. 10.1038/nchembio.69. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ja1c05376_si_001.pdf (4.5MB, pdf)

Articles from Journal of the American Chemical Society are provided here courtesy of American Chemical Society

RESOURCES